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Abstract Benzodiazepine use increases the risk of falls
and has been associated with an increased risk of hip
fractures. Our aim was to estimate the possible population
impact of the use of benzodiazepines on the rate of hip
fracture in France, Germany, Italy, Spain, the United
Kingdom, and the United States. We conducted a literature
review to estimate the pooled relative risk (RR) for hip
fractures and use of benzodiazepines. Prevalence rates of
benzodiazepine use in 2009 were calculated for each
country using the IMS MIDAS database and three public
databases in Denmark, the Netherlands, and Norway. Both
the RR and prevalence rates were used for calculation of
population attributable risks (PARs) of hip fractures asso-
ciated with benzodiazepine use. The literature review
showed an increased risk of hip fractures in benzodiazepine
users (RR = 1.4, 95 % CI 1.2–1.6). Rate of benzodiazepine
use showed considerable differences between countries,
ranging from 4.7 % to 22.3 % of population ever in a
1-year period. These are reﬂected in results for the PARs;
estimated attributions of benzodiazepines to the rate of hip
fractures were 1.8 %, 95 % CI 1.1–2.6 (Germany); 2.0 %,
95 % CI 1.2–2.8 (United Kingdom); 5.2 %, 95 % CI
3.2–7.3 (Italy); 7.4 %, 95 % CI 4.5–10.0 (France); 8.0 %,
95 % CI 4.9–11.0 (United States); and 8.2 %, 95 % CI
5.1–12.0 (Spain). PAR estimates suggest that the potential
attribution of benzodiazepine use on the population rate of
hip fractures in the ﬁve speciﬁed European countries and
the United States varies between 1.8 % and 8.2 %. During
the next phase of the IMI-PROTECT study, a comparison
with individual patient data will show whether this
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In 1990, there was an estimated total of 1.26 million hip
fracturesworldwide.Thisnumberisexpectedtoincreaseto2.6
million in 2025 and 4.5 million in 2050, mainly as a conse-
quence of population aging [1]. Hip fractures mainly affect the
elderly, especially women [2,3]. In general, hip fractures have
signiﬁcant consequences on individuals and health-care sys-
tems [2]. They are an important source of morbidity and
mortality: 20–30 % of hip fracture patients die within 1 year
after the fracture, and one-third are totally dependent or reside
in a nursing home after 1 year [4, 5]. Hip fractures can also
cause high managements costs; costs of one hip fracture are
estimated at US$21,000 in the ﬁrst year after surgery [2, 5, 6].
Osteoporosis is a common condition in the elderly, and
hip fractures are considered the most serious consequence
of osteoporosis [7]. The vast majority (90–95 %) of all hip
fractures result from falling [8]. Over the past 25 years,
epidemiological studies have reported a positive association
between falling, hip fractures, and use of benzodiazepines,
due to their sedative and muscle-relaxant effects [9, 10]. For
example, a recent meta-analysis [11] showed that risk of
falling was 1.5-fold increased in users of benzodiazepines.
There are no recently published studies comparing
consumption of benzodiazepines across multiple countries
and estimating their possible population impact on hip
fractures. Drug-consumption data at the patient level are
generally not publicly available in the largest European
Union (EU) countries and the United States. For this study
we used volume sales data of the Intercontinental Medical
Statistics (IMS) database. The IMS collects drug-utilization
data worldwide and attempts to do this in a standardized
way. Access to these data is subject to contract. This study
is part of the IMI PROTECT program, which is ‘‘a col-
laborative European project that comprises a programme to
address limitations of current methods in the ﬁeld of
pharmacoepidemiology and pharmacovigilance’’ [12]. Our
study explores the suitability of IMS data for pharma-
coepidemiological studies. Speciﬁcally, its aim was to
estimate the possible population impact of the use of
benzodiazepines on the rate of hip fracture in ﬁve large
European countries (France, Germany, Italy, Spain, and the
United Kingdom) and the United States.
Methods
In order to estimate the population impact of benzodiazepine
use on the rate of hip fracture in various countries, we calcu-
latedcountry-speciﬁc prevalencerates of benzodiazepine use.
Inaddition,areviewwasconductedtoobtainpooledrelative
risks (RRs) of the association between benzodiazepine use
and hip fractures. These were then combined into a popu-
lation attributable risk (PAR) using the following formula:
PAR% ¼
Pe RR   1 ðÞ
1 þ Pe RR   1 ðÞ
  100 ð1Þ
where Pe is prevalence of benzodiazepine use [13].
Literature Review
Databases PubMed, the Cochrane Library, and Embase
were systematically searched in September and October
2010 with terms that related to hip fractures and benzodi-
azepines. Unpublished studies were not considered.
Inclusion Criteria
Studies were includedifthefollowingcriteriawere reached:
(1) they were reviews or observational (prospective or ret-
rospective) and community-based (hospital-based studies
were excluded as they were considered to have a weaker
design because of the difﬁculty of ﬁnding appropriate con-
trols [14]), (2) outcome of interest was hip fracture, (3)
exposure of interest was current use of (long-acting and/or
short-acting) benzodiazepines, (4) they showed RRs or odds
ratios (ORs) and 95 % conﬁdence intervals (CIs), and (5)
they were published in English. During the ﬁrst literature
search, we included only observational studies and reviews
thatwerepublishedafterJanuary1,2000.Duringthesecond
literature search, we included observational studies from the
literature reviews, regardless of their publication date.
However,theseobservationalstudieshadtocomplywiththe
inclusion criteria.
Data Analysis
Cochrane Review Manager (version 5, http://www.coc
hrane.org/) was used to calculate a pooled RR and its 95 %
CI for each category under the assumption of a random-
effects model. We assumed that a hip fracture is a rare
disease and that the OR is an approximation of the RR.
Pooled RRs were estimated for different exposure catego-
ries; any benzodiazepine, short-acting benzodiazepines
(SABs) with elimination half-life (t)\24 hours, and long-
acting benzodiazepines (LABs) with t C24 hours.
Database Studies
Source Populations
In order to make projections of benzodiazepine use on
the country-speciﬁc PARs of hip fracture, available
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123benzodiazepine-sales data from the ﬁve large EU countries
France, Germany, Italy, Spain, and the United Kingdom
(2009); the United States (2009); Denmark (2007); the
Netherlands (2008); and Norway (2008) were retrieved
from the IMS database. Data from the Netherlands were
not the most recent data because the Dutch 2009 reim-
bursement data did not match IMS sales data of 2009. This
was a consequence of new benzodiazepine-reimbursement
regulations in January 2009 [15].
For our study we used the IMS Multinational Integrated
Data Analysis System (MIDAS) database, which is a com-
mercialdatabasethatcontainsdataonagloballevel.Insome
countries, IMS collects data only from pharmacies. How-
ever, in most countries, data are collected from sales from
wholesalers to retail or hospital pharmacies and sales from
manufacturerstoretailorhospitalpharmacies.TheIMSuses
a sample of a number of retail or hospital pharmacies and
wholesalers and projects this to estimate sales for all retail
and hospital pharmacies in a country. In the IMS MIDAS
database, data are registered per drug and for all its appli-
cation forms. These drugs are categorized according to the
AnatomicalClassiﬁcationofPharmaceuticalProductsofthe
European Pharmaceutical Marketing Research Association
(EphMRA) [16]. The IMS MIDAS database contains only
sales data in product volume, which we converted to the
World Health Organization’s (WHO’s) deﬁned daily dos-
ages (DDDs). In order to estimate the number of benzodi-
azepine users in IMS MIDAS, we used publicly available
sources of three countries (Denmark, the Netherlands,
Norway) that contained total numbers of DDDs as well as
numbers of users of a drug. We used data sources from these
three countries because equivalent types of databases from
theﬁvebigEUcountriesandtheUnitedStatesweremissing.
All three were online databases containing benzodiazepine
prescription data: the Register of Medicinal Product Statis-
tics of the Danish Medicines Agency [17], the Dutch
Genees-en hulpmiddelen Informatie Project (GIP) databank
[18], and the Norwegian Prescription Database (NorPD)
[19].ThedatabaseoftheDanishMedicinesAgencycontains
information, derived from Danish pharmacies, on pre-
scribed, reimbursed drugs and over-the-counter drugs [20].
The GIP databank was set up by the Dutch Health Care
Insurance Board and contains nonhospital data about pre-
scribed, dispensed, and reimbursed drugs [21]. The NorPD
database was developed by the Norwegian Institute of
Public Health; it receives data on all prescribed (reimbursed
ornot)anddispenseddrugstoallindividualpatientsinevery
Norwegian pharmacy [22].
Exposure: Medication Selected
In each IMS data source (i.e., for each country), we
retrieved all data on benzodiazepine use. Data on
benzodiazepines included in WHO ATC classes N05BA
(benzodiazepine derivates), N05CD (benzodiazepine deri-
vates), and N05CF (benzodiazepine-related drugs) were
analyzed [23]. Benzodiazepines with antiepileptic effects
(ATC class N03AE) were excluded because fracture risk is
already increased in epilepsy and this could have intro-
duced bias [24]. The selected benzodiazepines were then
subdivided into two groups: short-acting and long-acting.
This was done according to their elimination half-life in the
Micromedex [25].
Outcome Deﬁnition
One-year prevalence (YPr) was deﬁned as the number of
ever-users of benzodiazepines in a given calendar year
divided by the total population in that same calendar year.
These denominator population numbers were based on
data from Eurostat and the US Census Bureau [26, 27]. A
user was anyone who has had one or more prescriptions in
1 year. To estimate the number of users in each country,
ﬁrst IMS MIDAS sales data were converted into a number
of units of the WHO’s DDD. The WHO’s deﬁnition of a
DDD is ‘‘the average maintenance dose of a drug when
used on its major indication in adults’’ [28]. Then, this
total number of DDDs was used to calculate consumption
of DDDs per 1,000 denominator population per day
(DDD/1,000 persons/day). Expression of drug utilization
in DDD/1,000 persons/day allows aggregation of data that
differ in administration form and strength of dose and
makes it possible to compare drug use between countries
[28, 29].
Equation 2 shows a summary of the steps that were
taken to convert these DDDs/1,000 persons/day to country-
speciﬁc prevalence rates. For this estimation, we assumed
that the prevalence was proportional to DDD/1,000 per-
sons/day and that the ratio of mean (DDD/1,000 persons/
day)public databases to mean (DDD/1,000 persons/day)IMS
databases was equal in each country. We called this ratio the
‘‘conversion factor’’ and, setting the Danish, Dutch, and
Norwegian databases as a standard, multiplied all IMS data
by this factor.
Prevalence rate of benzodiazepine use ¼
A   B
C
ð2Þ
where A is country-speciﬁc benzodiazepine consumption in
DDD/1,000 persons/day (IMS databases, converted with
conversion factor); B is mean prevalence of benzodiaze-
pine use in Denmark, the Netherlands, and Norway (Danish
registries, Dutch GIP databank, Norwegian NorPD data-
base); and C is mean benzodiazepine consumption in
DDD/1,000 persons/day in Denmark, the Netherlands,
and Norway (Danish registries, GIP databank, NorPD
database).
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123Analysis (Combination of Literature Review
and Database Studies)
The primary outcome of this study was the PAR. This is a
measure that estimates how many hip fractures could be
prevented if exposure to the risk factor, in this case ben-
zodiazepine use, was eliminated [30]. PARs for each
country were estimated using the pooled RR and preva-
lence (equation 1). This was done for each benzodiazepine
category (any benzodiazepine, SABs, and LABs).
We also conducted a sensitivity analysis by calculating
PARs for the whole population and for men and women
65 years and older in Denmark and Norway. YPr values
were calculated using numbers of DDDs and numbers of
users in the Danish and Norwegian databases and popula-
tion data from Eurostat.
Results
We identiﬁed 11 studies that met the inclusion criteria and
were included for the calculation of pooled RRs for hip
fractures and benzodiazepines. Five of these studies were
published before January 1, 2000, but were included in
review studies that were published after this date. There-
fore, they also contributed to our study.
Figure 1 shows that the risk of hip fractures was 1.4-fold
increased in users of any benzodiazepine (RR = 1.40, 95 %
CI 1.24–1.58). Pooled RRs for users of SABs and LABs
were both lower: 1.23 (95 % CI 1.09–1.39) and 1.32 (95 %
CI 1.10–1.58), respectively (Figs. 2, 3). There was no
substantial difference between the pooled RR of cohort
studies (1.32, 95 % CI 1.17–1.48) and the pooled OR of
case–control studies (1.43, 95 % CI 1.20–1.71). Figures 1–
3 also show the results for the heterogeneity tests. I
2, given
in percentages, quantiﬁes how much of the variation in RRs
from the included studies is a result of genuine differences
between the studies rather than chance [31]. In our study, I
2
varied between 42 % and 66 %, i.e., a moderate variation
[32].
Table 1 shows that there were considerable differences
in benzodiazepine use across countries. The average of
benzodiazepine consumption per day was highest in Spain
(85.5 DDD/1,000 persons/day) and the United States (82.9
DDD/1,000 persons/day). In each country, SABs were
consumed more than LABs. As described in Methods,
DDDs/1,000 persons/day, calculated with IMS data, were
all multiplied by a conversion factor, which was 0.937.
One-year prevalence rates of benzodiazepine use, cal-
culated using the DDDs/1,000 persons/day, ranged
between 4.7 % (Germany) and 22.3 % (Spain). Further-
more, prevalence rates were estimated to be between 3.0 %
(Germany) and 19.7 % (United States) for SABs and 1.0 %
(Germany) and 4.7 % (Spain) for LABs. These numbers
were used to calculate the PARs.
Table 2 shows that the estimated attribution of use of
any benzodiazepine on the risk of hip fractures varied
between 1.8 % and 8.2 % and that in all countries this
PAR was higher than the PARs of the two subgroups.
Also, in each country, the attribution of SABs was higher
than that of LABs. The PARs of any benzodiazepine and
LABs were highest in Spain (respectively, 8.2 % and
1.5 %), while the PAR of SABs was highest in the United
States (4.3 %).
Fig. 1 Forest plot of relative
risks for hip fractures and use of
benzodiazepines versus nonuse.
Squares represent the relative
risk in each study; their sizes are
proportional to their weights.
Horizontal lines represent 95 %
conﬁdence intervals. Black
diamonds represents the pooled
relative risk (calculated with a
random-effects model). Studies
are ordered according to their
weights
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Denmark and Norway the PARs calculated for men and
women 65 years and older were considerably higher
compared to the PARs that were based on the whole
population. Also, the attributable risk for hip fractures
associated with benzodiazepine use was about twice as
high for elderly women compared to elderly men.
Discussion
This study found that the estimated impact of benzodiaz-
epine use on hip fracture rate varied between 1.8 % and
8.2 % in the six countries studied (Table 2). These differ-
ences are a result of the considerable differences in ben-
zodiazepine use between these countries; DDDs/1,000
persons/day varied from 18 to 86 (Table 1). In all coun-
tries, the PAR of SABs was higher than that of LABs. This
suggests that a larger proportion of hip fractures may be
associated with the use of SABs than the use of LABs.
Review of observational studies has shown that all ben-
zodiazepines, as well as the two subgroups separately, are
associated with an increased risk of hip fractures. This
relationship can be explained by an increased risk of falls
Fig. 2 Forest plot of relative
risks for hip fractures and use of
short-acting benzodiazepines
versus nonuse. Squares
represent the relative risk in
each study; their sizes are
proportional to their weights.
Horizontal lines represent 95 %
conﬁdence intervals. Black
diamonds represents the pooled
relative risk (calculated with a
random-effects model). Studies
are ordered according to their
weights
Fig. 3 Forest plot of relative
risks for hip fractures and use of
long-acting benzodiazepines
versus nonuse. Squares
represent the relative risk in
each study; their sizes are
proportional to their weights.
Horizontal lines represent 95 %
conﬁdence intervals. Black
diamonds represents the pooled
relative risk (calculated with a
random-effects model). Studies
are ordered according to their
weights
Table 1 Benzodiazepine use (DDD/1,000 persons/day) in ﬁve
European countries and the United States, calculated using IMS
MIDAS drug sales data (2009)
Country Any benzodiazepine SAB LAB
France 76.0 64.1 11.9
Germany 18.0 14.0 3.91
Italy 52.4 42.4 10.0
Spain 85.5 67.9 17.6
UK 19.3 11.6 7.63
US 82.9 75.9 6.96
DDD WHO’s deﬁned daily dose, SAB short-acting benzodiazepine,
LAB long-acting benzodiazepine
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123associated with benzodiazepine use. Previous studies
reported increased falls and increased risk of hip fracture
with use of LABs [33–36], while others found the same
association for SABs [37–39]. Some studies found an
increased risk for both benzodiazepine types, with higher
risks for LABS compared to SABs [34, 35, 40]. This can be
explained given that SABs have less potential for accumu-
lation and prolonged sedative effects [34]. In contrast,
Chang et al. [37] suggested that SABs may show more
severe withdrawal symptoms, more rapid tolerance devel-
opment,and more cognitive impairment and could therefore
lead to a higher association with hip fractures than LABs.
As shown in Table 2, the PARs of SABs and LABs
cannot be combined to obtain the PAR of the total group of
benzodiazepines; this is a result of different studies that
were used to calculate the RRs of these three categories.
For calculation of the RR of ‘‘any benzodiazepine,’’ several
extra studies were included that were not included in the
calculation of the RR of SABs or LABs as results were not
split by duration of action.
The heterogeneity tests in the Cochrane Review
Manager (Figs. 1–3) showed that the heterogeneity (I
2)
was between 42 % and 66 %, indicating moderate
heterogeneity [32]. The pooled RR for the total group of
benzodiazepines showed the highest I
2 value, probably
because this group consists of studies using different types
of exposure (SABs or LABs).
A strength of the IMS is that data collection is similar
across countries. This allows comparison between these
countries. However, the IMS MIDAS database does not
contain the number of users of a drug but rather the total
quantityofa drug used per country. Therefore, we estimated
numbers from IMS volume data and built in a conversion
factor based on the volume data and number of recipients
from three public databases. A single estimate of use of
benzodiazepines was used for each country, while regional
variation is likely to exist. Another limitation is that we had
to make certain assumptions when estimating the 1-year
prevalence rate. A conversion factor, calculated from dat-
abases of three northern European countries, was used to
calculate 1-year prevalence rates for other countries. Fur-
thermore, we did not assume a change of risk from drug use
over time. Literature about this so-called hazard function is
limited on benzodiazepines. There was also a limitation in
estimating the pooled RR; only observational studies were
used because no data from clinical trials were available.
These observational studies are subject to various forms of
bias [41–43]. Also, all of these studies used populations
65 years and older, which could lead to an inaccurate esti-
mation ofRRs and, thus, the PARsforthe whole population.
Another issue is the fact that benzodiazepines are used
mainly by women and the elderly [44–47]. Thus, the two
groups with highest risk for hip fractures are also the groups
that are most exposed to benzodiazepine use. This possibly
causes an underestimation of the PARs because in this study
it was assumed that benzodiazepine use is equally distrib-
uted over the whole population. The sensitivity analysis,
which showed that the PAR is indeed higher for the elderly
and especially for older women, conﬁrms this.
In conclusion, in our study the estimated attribution of
benzodiazepine use on the rate of hip fractures varied
between 1.8 % and 8.2 %. This suggests that in each of the
studied countries, a substantial number of hip fractures may
be associated with the use of benzodiazepines. These
numbers are different in each country, reﬂecting differ-
ences in consumption of these drugs. Although some
assumptions were made in deriving these estimates, this
study shows the possibility to use the IMS MIDAS data-
base for country comparisons of benzodiazepine con-
sumption. During the next phase of the IMI-PROTECT
study, a comparison with individual patient data will show
whether our approach can reliably estimate the impact of
benzodiazepines on hip fractures in different countries. We
consider databases with drug-consumption data from
multiple countries to be valuable when studying similar
questions with both other drugs and other outcomes.
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